XML 34 R15.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Goodwill and Intangible Assets
 12 Months Ended
Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
The changes in the carrying amount of goodwill for fiscal 2024 are as follows (in thousands):
HPACSGACGTotal
Balance as of April 1, 2023 (1)
$501,602 $525,351 $1,733,860 $2,760,813 
Goodwill impairment— (221,414)— (221,414)
Goodwill resulting from Anokiwave acquisition (2)
16,140 — — 16,140 
Effect of changes in foreign currency exchange rates— 1,062 — 1,062 
Goodwill reclassified to "Assets of disposal group held for sale" (3)
(200)(4,700)(17,100)(22,000)
Balance as of March 30, 2024 (1)
$517,542 $300,299 $1,716,760 $2,534,601 
(1) The Company’s goodwill balance is presented net of accumulated impairment losses and write-offs totaling $903.4 million and $682.0 million as of March 30, 2024 and April 1, 2023, respectively, which were recognized in fiscal years 2009, 2013, 2014, 2022, 2023 and 2024.
(2) Refer to Note 6 for additional information.
(3) Refer to Note 4 for additional information.

The Company operates under three segments with a total of seven reporting units as of March 30, 2024. During fiscal 2024, the Company completed the sale of its non-core biotechnology business, which was a stand-alone reporting unit.

During the second quarter of fiscal 2024, the Company completed an interim test for goodwill impairment as management determined, based on revisions to long-term forecasts, it was more likely than not that the fair value of a reporting unit within the CSG segment was below its carrying amount. The quantitative analysis, which considered the income approach and the market approach to estimate the reporting unit's fair value, resulted in a goodwill impairment charge of approximately $48.0 million. In the third quarter of fiscal 2024, the Company concluded that an impairment triggering event occurred for this same reporting unit as new information was received regarding slower than expected market adoption for one of CSG's new technologies and lower attach rates for a second CSG technology (resulting in further revisions to the long-term forecasts of this reporting unit). The Company concluded that it was more likely than not that the fair value of this reporting unit was below its carrying amount and a quantitative analysis was performed. The quantitative analysis, which considered the income approach and the market approach to estimate the reporting unit's fair value, resulted in a goodwill impairment charge of approximately $173.4 million.

In fiscal 2023, the Company recorded a goodwill impairment charge of $12.4 million related to its biotechnology business. In fiscal 2022, the Company recorded a goodwill impairment charge of $48.0 million related to its NextInput business.

The following summarizes information regarding the gross carrying amounts and accumulated amortization of intangible assets (in thousands):
 March 30, 2024April 1, 2023
 Gross
Carrying
Amount		Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization
Developed technology $903,089 $484,347 $872,106 $382,448 
Customer relationships 100,040 67,999 104,616 67,485 
Technology licenses 54,869 6,525 1,664 513 
Trade names 1,610 939 910 789 
IPRD 9,585 N/A9,642 N/A
Total (1)
$1,069,193 $559,810 $988,938 $451,235 
(1) Amounts include the impact of foreign currency translation.
At the beginning of each fiscal year, the Company removes the gross asset and accumulated amortization amounts of intangible assets that have reached the end of their useful lives and have been fully amortized. Useful lives are estimated based on the expected economic benefit to be derived from the intangible assets. In connection with completing the Company's fiscal 2024 goodwill impairment assessments, the Company also evaluated its long-lived intangible assets and determined that the forecasted undiscounted cash flows related to these assets were in excess of their carrying values. No definite-lived intangible asset impairment charges were recorded for fiscal years 2024, 2023 or 2022.

Total intangible assets amortization expense was $127.9 million, $132.4 million and $150.5 million in fiscal years 2024, 2023 and 2022, respectively.

The following table provides the Company's estimated amortization expense for intangible assets for the periods indicated (in thousands):
Fiscal Year Estimated
Amortization
Expense
2025$134,000 
2026123,000 
202799,000 
202858,000 
202936,000